@Tat_TvamAsi@IntensityInc I feel you… I’ve been In a lot shorter
But 20plus meetings at bio even a single small deal would send us and quicken it a lot!
But since we have big partners involved they may not be too happy selling bits to others..
I’m feeling good
Mark your calendar.
Join us on Tuesday, August 11 at 8:00 a.m. ET as Intensity Therapeutics reports second quarter 2026 financial results and shares a corporate update, including progress across our clinical development programs.
Learn more here: https://t.co/KtG20N1hso
#IntensityTherapeutics #Oncology #CancerResearch #ClinicalTrials $INTS
@IntensityInc Make us proud mr bender
One validation with upfront cash to run trials and expand with milestone’s instant tension release and opportunity to raise at amazing prices then we have validation cash and a straight and narrow path to saving life’s.
Thanks Joel
Speaking with @AsiaBioSpectrum at #BIO2026, $INTS' Founder and CEO, Lew Bender, discussed how intratumoral therapies may help turn tumors into personalized anti-cancer vaccines while reducing systemic toxicity.
Full interview: https://t.co/UvyKv3qNqQ
#BIOUS
#ICYMI: Lewis Bender, CEO of $INTS, recently shared insights with Biopharma Boardroom on the potential of INT230-6 and the evolving future of intratumoral therapies.
Catch up here: https://t.co/2vmhHWvdnr